Fungizone (amphotericin B) Oral Suspension

    Bristol-Myers Squibb is finally marketing Fungizone (amphotericin B) Oral Suspension...for treating oral candidiasis.

    This suspension was approved over 25 years ago. But it's just now being marketed because of the increasing incidence of oral candidiasis...particularly in patients with HIV or cancer.

    Patients use the oral suspension QID...swish and swallow.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote